



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Hijazi, Z;Yassi, N;O'Brien, JT;Watson, R

Title:

The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia

Date:

2022-04-01

Citation:

Hijazi, Z., Yassi, N., O'Brien, J. T. & Watson, R. (2022). The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia. *European Journal of Neurology*, 29 (4), pp.1254-1265. <https://doi.org/10.1111/ene.15211>.

Persistent Link:

<https://hdl.handle.net/11343/336319>

**Title:**

**The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia**

**Authors:**

Zina Hijazi, MBBS, FRACP<sup>1,2</sup>, Nawaf Yassi, PhD<sup>3,4,5</sup>, John T. O'Brien DM<sup>6</sup>, Rosie Watson, MBBS, FRACP, PhD<sup>3,4</sup>

(1) Monash University School of Rural Health, Bendigo Hospital, Bendigo, VIC, Australia

(2) Department of Medicine - Bendigo Hospital, Bendigo, VIC, Australia

(3) Department of Medicine - Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia

(4) Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

(5) Department of Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia

(6) Department of Psychiatry, University of Cambridge, Level E4, Box 189, Cambridge. CB2 0QC. UK

**Corresponding author:** Zina Hijazi, email: [zinahijazi@bendigohealth.org.au](mailto:zinahijazi@bendigohealth.org.au)

**Keywords:** Lewy body disease, neuroimaging, cerebrovascular disorders

**Running title:** Vascular disease in Lewy body dementias

**Word count:** 3464 including abstract, abstract: 230

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ENE.15211](https://doi.org/10.1111/ENE.15211)

This article is protected by copyright. All rights reserved

Article type : Review Article

**Abstract:**

**Introduction:** Lewy body dementia (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is a common form of neurodegenerative dementia. The frequency and influence of comorbid cerebrovascular disease is not understood but has potentially important clinical management implications.

**Methods:** A systematic literature search was conducted (Medline and Embase) for studies including participants with DLB and/or PDD assessing cerebrovascular lesions (imaging and pathological studies). They included white matter changes, cerebral amyloid angiopathy (CAA), cerebral microbleeds (CMB), macroscopic infarcts, micro-infarcts and intracerebral haemorrhage.

**Results:** Of 4411 articles, 63 studies were included. Cerebrovascular lesions commonly studied included white matter changes (41 studies) and CMB (18 studies). There was an increased severity of white matter changes on magnetic resonance imaging (visualized as white matter hyperintensities, WMH), but not neuropathology, in LBD compared to PD without dementia and age-matched controls. CMB prevalence in DLB was highly variable but broadly similar to Alzheimer's disease (AD) (0-48%), with a lobar predominance. No relationship was found between large cortical or small subcortical infarcts or intracerebral haemorrhage and presence of LBD.

**Conclusion:** The underlying mechanisms of WMH in LBD require further exploration, as their increased severity in LBD was not supported by neuropathological examination of white matter. CMB in LBD had a similar prevalence as AD. There is a need for larger studies assessing the influence of cerebrovascular lesions on clinical symptoms, disease progression and outcomes.

## Introduction

Lewy body dementia (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is a common form of neurodegenerative dementia. Clinical features of DLB include fluctuating cognition, recurrent visual hallucinations, rapid eye movement sleep behavior disorder and parkinsonism<sup>1</sup>. PDD has similar features to DLB but is diagnosed when the onset of dementia is at least one year after established parkinsonism<sup>1</sup>. Lewy body pathology, involving aggregation of the synaptic protein  $\alpha$ -synuclein, characterizes LBD and is prevalent in is up to 5% in the general population and up to 30% in people with dementia<sup>1-3</sup>.

Comorbid pathology, including amyloid- $\beta$ , tau and cerebrovascular disease occurs commonly in dementia, including LBD<sup>4</sup>. Cerebrovascular disease is of particular interest as there are potential prevention and treatment options. In dementia, it is unclear whether cerebrovascular disease interacts with the neurodegenerative process or whether its effect is purely additive, although in Alzheimer's disease, the trajectory of cognitive decline may be accelerated by the presence of cerebrovascular disease<sup>5</sup>. Cerebrovascular disease has multiple manifestations that can be detected on neuroimaging and neuropathological examination. The following cerebrovascular lesions will be examined in this review and have been associated with cognitive decline: white matter changes, cerebral microbleeds and minibleeds, cerebral amyloid angiopathy, cortical and subcortical infarcts and intracerebral haemorrhage and microinfarcts<sup>6-17</sup>.

White matter changes can be seen either on MRI ("white matter hyperintensities", WMH) or detected on neuropathological examination ("white matter lesions", WML). WMH may represent ischaemic tissue damage, with disruption of the blood brain barrier and leakage of plasma and may develop from small clinically silent infarcts<sup>18-21</sup>. They may have different aetiologies based on location (fig 2); peri-ventricular WMH may be caused by ischaemic damage due to atherosclerosis, while deep subcortical WMH are associated with small vessel disease and presence of lacunar infarcts<sup>18,22</sup>.

Cerebral microbleeds (CMB), which consist of haemosiderin and are associated with lipofibrohyalinosis of the cerebral vasculature, have also been associated with cognitive impairment<sup>23-10-14</sup>. CMB have an increased prevalence in AD (18-32%), which may be due to an increased prevalence of CAA as CMB in the lobar regions are associated with CAA<sup>23-25</sup>. They are seen on MRI as black round or ovoid lesions with a blooming effect on susceptibility-weighted MRI, usually between 2-10mm in diameter<sup>26,27</sup>. Mini-bleeds, another type of small cerebral bleeds, are defined as an accumulation of erythrocytes or siderophages in the perivascular region and are only visible microscopically<sup>11,28</sup>. CMB quantification in research can be through manual counting or a semi-quantitative ranking scale. More recently, automated methods have been explored and may have increased sensitivity, although specificity is limited<sup>29-31</sup>.

CAA is another cerebrovascular lesion that, although associated with the presence of AD pathology, may contribute to cognitive decline independently of AD pathology<sup>15,16</sup>. CAA results from deposition of  $\beta$ -amyloid ( $A\beta$ ) in the cerebral and meningeal vasculature (mainly arteries and arterioles), with an increasing prevalence with age<sup>32</sup>. It can be diagnosed on cerebral imaging using certain criteria (e.g. the Boston criteria), but the gold standard is histopathological diagnosis<sup>33</sup>.

Cerebral microinfarcts (definitions vary from microscopic infarcts to infarcts that up to 5mm in size) have been linked with development of dementia, even in the absence of other pathology (e.g. Alzheimer's disease)<sup>17</sup>. They are detected on microscopic examination at autopsy (e.g. with a semi-quantitative scale), although more recently studies have detected micro-infarcts using 7T and 3T MRI<sup>34</sup>.

This comprehensive review examines the frequency and influence of cerebrovascular disease in LBD. Results of neuroimaging and neuropathological studies of vascular brain disease in LBD are discussed and recommendations for future work are provided.

## Methods

A systematic literature search was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines<sup>35</sup> using the electronic databases Medline and Embase for articles in English from the database inception to 21<sup>st</sup> July 2021. Reference lists were also systematically checked for relevant articles. Studies included assessed the presence and/or location of cerebrovascular lesions on either magnetic resonance imaging (MRI) or neuropathological studies of DLB or PDD. Case reports, conference abstracts and studies including < 5 participants with LBD were excluded. The search terms included both keywords and subject headings. The Embase search strategy (from inception until July 2021 when the search was run) was as follows:

((white matter lesion\* or white matter hyperintensit\* or cerebral amyloid or angiopathy or vascular or cerebrovascular or stroke or infarct\* or microinfarct\* or microvascular or hemorrhage\* or microbleed\* or micro-bleed\*).tw or white matter injury/ or white matter lesion/ or vascular amyloidosis/ or cerebrovascular accident/ or occlusive cerebrovascular disease/ or brain infarction/ or intracerebral bleeding/ or intracerebral haemorrhage/) AND ((Parkinson\* or Lewy).tw or parkinson disease/ or parkinson dementia complex/ or symptomatic parkinson disease/ or diffuse lewy body disease/ or lewy body/) AND (autopsy/ or nuclear magnetic resonance imaging/ or (magnetic resonance imaging or neuropatholog\* or autopsy).mp) AND limit to (human and English language). We conducted a narrative review of the literature based on the findings of the systematic literature review.

## Results

Sixty-three studies were included (fig 1), with studies on white matter lesions (N=42), cerebral microbleeds and mini-bleeds (N=18), cerebral amyloid angiopathy (N=16), large cortical and small subcortical infarcts (N=17), microinfarcts (N=12) and intracerebral haemorrhage (N=8). There was commonly more than one lesion examined in each particular study.

### White matter lesions of presumed vascular origin

Studies on white matter lesions included MRI studies (N=31) and neuropathological studies (N=11). MRI studies (LBD participant numbers ranged from N=8 - 165)

This article is protected by copyright. All rights reserved

compared LBD participants to healthy controls, AD, and PD. Most MRI studies showed an increased prevalence and/or severity of deep and peri-ventricular WMH in LBD compared to PD without dementia and age-matched controls (table 1)<sup>36-49</sup>. Sarro et al (2017) included one of the largest DLB participant groups (n=81) and used 3T MRI with a semi-automated method of WMH quantification (corrected for brain volume), which was increased in DLB compared to aged-matched controls<sup>36</sup>. Several longitudinal studies found an association between WMH in PD and progression to PDD, but in others, WMH was not associated with progression to PDD after accounting for other confounding variables (e.g. age, CSF A $\beta$  and hippocampal volume)<sup>47,50-56</sup>.

Although some studies suggested an increased severity of MRI WMH in DLB compared to PDD, particularly in the parietal and occipital regions<sup>40,57</sup>, others did not find a statistically significant difference; the differing results may be due to a different WMH measurement method, differing population groups or a relatively small sample size of DLB participants<sup>38,42</sup>.

There was a similar prevalence and severity of MRI WMH in DLB and AD in the peri-ventricular<sup>37,40,41,58-60</sup> and deep white matter<sup>37,40,41,58,59</sup>, with the posterior periventricular and occipital regions being more affected in DLB compared to AD<sup>36</sup>. However, a study by Kenny et al (2004) suggested that only the deep WMH (but not peri-ventricular or basal ganglia hyper-intensities) were more severe in DLB (n=38) than AD (n=52)<sup>60</sup>. This finding suggests the possibility of a separate mechanism for development of peri-ventricular WMH in AD, such as an increased water content in the peri-ventricular white matter related to cortical degeneration<sup>22</sup>. It has been suggested that WMH in AD may be a core feature involved in its pathogenesis, although the mechanism is yet unknown<sup>61</sup>.

Neuropathological studies included between 8 and 48 LBD participants and mainly compared WML to controls. They examined a selected number of brain sections and used a semi-quantitative rating scale (table 2)<sup>11,28,62-64</sup>. The prevalence of WML in LBD ranged from 25-48%, compared to 4-31% in controls. Types of WML were mostly unspecified, but in some studies were defined as axonal or myelin loss. Unlike MRI studies, neuropathology studies mostly found similar rates of WML in

LBD compared to age-matched controls<sup>11,28,62,63,65,66</sup>. Other studies suggested a relationship between WML and LBD, although interpretation of some of the results may have been confounded by other variables such as age of participants<sup>6,67,68 69</sup>.

There does not appear to be a clear correlation between WML and clinical outcomes in LBD, either in the presence of core clinical features, dementia severity or motor scores, although REM sleep behaviour disorder has been associated with lower WMH volume in DLB<sup>36,70</sup>. Ferreira et al (2021) studied 165 DLB participants and reported that a higher WMH burden was associated with presence of visual hallucinations in DLB<sup>71</sup>. Conversely, Barber (1999) reported that occipital WMH were associated with the absence of visual hallucinations and delusions, but this was a smaller study (27 DLB participants) and also included other dementia types in the analysis<sup>37</sup>. Two cross-sectional studies found that WMH severity correlated with reduced scores on neuropsychiatric testing (including Mini Mental State Examination, Clinical Dementia Rating and the Seoul Verbal Learning Test)<sup>38,71</sup>. Furthermore, there may be an association between autonomic dysfunction, which is a supportive feature for the clinical diagnosis of DLB, and the severity of deep but not periventricular WMH<sup>1,72</sup>.

### **Cerebral microbleeds and mini-bleeds**

Eighteen studies examined CMB and mini-bleeds in LBD (N=7 – 91 participants), but there were some conflicting results and possible study biases. Most studies compared DLB to controls, but the other comparison groups also included AD, PD and PDD. The prevalence of CMB in DLB ranged from 0-48% and in controls from 0-50% (table 3). Four autopsy studies reported similar rates of CMB in DLB compared to age-matched controls, although mini-bleeds had an increased frequency<sup>11,28,63,66,73</sup>. In contrast, other studies reported an increased prevalence of CMB in DLB (45%) compared to PDD (26%) and controls (17%) and in PDD (35%) compared to PD with mild cognitive impairment and PD (prevalence of 15% in both)<sup>42 44,46</sup>. Variability in characteristics between LBD participants and controls may have contributed to the differences in these results, for example differences in age and prevalence of cardiovascular risk factors between groups in some of the studies<sup>28,67</sup>.

In comparison to AD, several studies showed a similar prevalence of CMB in DLB <sup>58,64,73-76</sup>. CMB and mini-bleeds were more prevalent in lobar rather than deep and infra-tentorial regions, where rates were similar to controls <sup>11,28,42,67,75-77</sup>. Although this suggests that CMB in LBD may be related to AD-related pathology, including CAA, studies have not supported this theory. Donaghy et al (2020) examined 30 DLB participants using MRI and amyloid PET imaging and did not find an association between amyloid and presence of CMB <sup>75</sup>. Two smaller neuropathological studies by de Reuck et al (2013 and 2015) also explored this and found no significant difference was found in CMB and mini-bleeds between DLB participants with AD and CAA pathology and those without <sup>63,67</sup>. Mendes et al (2021) included 91 DLB participants and did not find an association between CMB in DLB and presence of cerebrospinal fluid AD biomarkers, including tau, phosphorylated tau and amyloid- $\beta$  (1-42) <sup>76</sup>. An alternative proposed theory is that CMB in LBD may be associated with increased angiogenesis related to Lewy body pathology <sup>67,78</sup>. Fukui et al (2013) assessed clinical and imaging correlations of CMB in DLB. An increased number of CMB was associated with cognitive rather than motor impairment at onset of the disease <sup>58</sup>. In some studies, DLB participants with CMB had lower scores on neuropsychological testing than those without, but this association was not found in other studies <sup>75,76,79</sup>.

### **Cerebral amyloid angiopathy (CAA)**

Sixteen studies examined CAA in LBD (N=13 - 110 participants) by examining a certain number of brain regions and most studies used a semi-quantitative ranking scale <sup>80</sup>. CAA prevalence was compared between DLB, PDD, AD and controls. Some studies distinguished between DLB with coexisting AD pathology and those without. The prevalence and severity of CAA in LBD appeared to be increased compared to participants with PD without dementia <sup>47,81-83,62,84,85</sup>. Prevalence of CAA ranged from 6-100% in LBD, 58-100% in AD, and 0-50% in controls (table 4). In an autopsy study by Jellinger et al (2021) including 170 LBD cases, the prevalence of CAA was higher in DLB (93%) than PDD (50%) and PD (22%)<sup>84</sup>. It is important to note that several studies that controlled for AD co-pathology in LBD suggest that CAA prevalence may be related to AD co-pathology, as the prevalence was lower in LBD without AD co-pathology <sup>86,87,83</sup> and in some cases was similar to the prevalence

in healthy controls<sup>88</sup>. Whether CAA itself is a contributor to cognitive decline in LBD or whether these results are indicative of AD co-pathology in those with dementia is yet to be explored.

### **Large Cortical Infarcts and small subcortical infarcts**

Seventeen studies examined large cortical and small subcortical infarcts (N=8 - 165 LBD participants) and comparison groups included controls, AD and PD. Most reported a similar prevalence of these changes in LBD and controls<sup>11,28,36,39,42,63,67,86,89,90</sup>. Ferreira et al (2021) included 165 DLB participants and noted that infarcts (>3mm) assessed on MRI were more common in subcortical than cortical regions (13% vs 2%, respectively) and were associated with presence of WMH<sup>71</sup>.

One study by Ghebremedhin et al (2010) raised the possibility of an inverse relationship between cerebrovascular lesions (including small vessel disease and atherosclerosis in the circle of Willis assessed using a semi-quantitative scale and infarct prevalence in brain sections) and the extent of Lewy body pathology in DLB (n=13) compared to controls (n=53)<sup>1,62</sup>. However, these findings differ from other findings in the literature and the authors note that the association observed in this study could be a result of cerebrovascular lesions lowering the threshold for developing clinical symptoms of DLB.

In comparison to AD, three studies reported no statistically significant difference in the prevalence of infarcts in LBD<sup>39,64,73</sup>. One neuropathological study by Londos et al (2000) examined frontal white matter changes, including both non-specific white matter changes and infarcts, and found that overall these were increased compared to AD<sup>91</sup>.

### **Microinfarcts**

Twelve studies assessed micro-infarcts in LBD (N=7 - 25 LBD participants), mainly in comparison with controls. There may be an increased prevalence of microinfarcts in LBD (range 15-80%) compared to controls (range 10-35%, table 6). In two

neuropathological studies, the severity of microinfarcts was greater in DLB than controls and in the study by Ghebremedhin et al (2010), microinfarcts were more common in participants with severe Lewy body pathology<sup>62,67</sup>. Although other studies did not find a statistically significant difference in microinfarcts in DLB compared to controls, their sample sizes were relatively small<sup>11,28,63,90</sup>.

There were conflicting results regarding the prevalence of microinfarcts in DLB compared to AD. De Reuck et al (2017) found an increased number of microinfarcts in both neuropathological and post-mortem MRI examination of brains with Lewy body pathology (either “pure” DLB or with AD co-pathology) compared to those with pure AD pathology<sup>64</sup>. In contrast, Isojima et al (2006) found microinfarcts to be less prevalent on neuropathological examination of DLB brains (40%) compared to AD brains (68%)<sup>73</sup>. The reason for these conflicting results is unclear, but in the study by De Reuck et al (2017), there were differences between participant groups in prevalence of hypertension, which may be a risk factor for microinfarcts<sup>92</sup>.

### **Intracerebral haemorrhage**

In comparison with controls, most of the eight studies examining intracerebral haemorrhage reported a similar prevalence in LBD compared to controls (table 5)<sup>11,28,63,66,67,86,90</sup>. Isojima et al (2006) reported increased prevalence of intracranial haemorrhage in DLB compared to AD, but this also included non-cerebrovascular causes (i.e. subdural haemorrhage)<sup>73</sup>.

### **Discussion and conclusions**

Studies examined a range of cerebrovascular lesions in LBD. There was an increased severity of WMH changes on MRI in LBD compared to PD without dementia and age-matched controls, but this result was not found for neuropathological WML. CMB prevalence in LBD was highly variable but broadly similar to AD (0-48%), with a lobar pattern. Microinfarcts were found to be more prevalent in LBD compared to controls in some studies. No relationship was found between large cortical or small subcortical infarcts or intracerebral haemorrhage and presence of LBD.

The most widely studied cerebrovascular change in LBD was WMH of presumed vascular origin on MRI brain, where most studies reported an increased burden in

LBD compared to age-matched controls. There was also a possible relationship between WMH burden and progression from PD to PDD in longitudinal studies. The pathogenesis of WMH may be closely related to AD, and whether this is the case with LBD remains unknown<sup>61</sup>. There was increasing use of more advanced imaging methods in the more recent studies (3T MRI or 7T post-mortem MRI). Some studies used an automated approach to WMH quantification, which although are more complex to implement than VRS (e.g. Fazekas or Scheltens scales), may have increased accuracy and reproducibility<sup>22,93-96</sup>. Interestingly, neuropathology studies did not support the increased prevalence of WML of presumed ischaemic origin in LBD compared to controls, which raises the importance of clarifying the underlying pathology of the WMH visualised on MRI in LBD. One possibility is that an alternate pathology to cerebrovascular disease, such as inflammation or demyelination, results in the appearance of the WMH on MRI<sup>97</sup>. Alternatively, MRI may be more sensitive in detecting white matter changes compared to neuropathology which examines selected brain sections.

Another commonly studied lesion was CMB and mini-bleeds, where conclusions were difficult due to variable study methodology, for example in controlling for cerebrovascular risk factors. Some studies reported an increased prevalence in LBD compared to age-matched controls while others did not, and there appeared to be a similar prevalence of CMB in LBD compared to AD. There was an increased prevalence of CMB in the lobar rather than deep and infra-tentorial regions in LBD. The data suggested that CAA in LBD may be increased compared to those without LBD, but may be related to AD co-pathology. Microinfarcts, which were studied both on neuropathological examination and post-mortem MRI, were found to be more prevalent in some studies but not others, with differing participant groups between studies and small sample sizes.

The prevalence of other cerebrovascular lesions, including large cortical infarcts, small subcortical infarcts and intracerebral haemorrhage, did not appear to differ between people with LBD and age-matched controls.

Within the studies, methods of lesion detection and definition of lesions varied. There was also variability in the participant population between studies and many had a relatively small sample size. As a result, there were inconsistencies between studies, with no clear relationship arising between the prevalence of a specific cerebrovascular lesion type and the diagnosis of LBD or clinical outcomes. However,

certain patterns were observed with some cerebrovascular lesions that may inform future studies. Future research in this area would benefit from more consistent cerebrovascular lesion definitions and lesion detection methods. Recommendations for imaging standards for cerebrovascular disease research are available and include suggestions regarding minimum essential MRI sequences and VRS use<sup>98</sup>. Future research should also have consistent adjustment for both clinical and pathological variables to determine the effect of cerebrovascular lesions on LBD and its progression.

In conclusion, there may be an increased prevalence of certain cerebrovascular lesions (WMH, CMB and CAA) in LBD compared to age-matched controls. LBD did not appear to affect the prevalence of large cortical or small subcortical infarcts or intracerebral haemorrhage. Data were lacking with regards to the effect of the presence of such lesions on clinical outcomes in LBD. There is a need for larger studies assessing the influence of cerebrovascular lesions on clinical symptoms, disease progression and outcomes.

## References

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium. *Neurology*. 2017;89(1):88-100.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski J, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-840.
3. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. *Age and Ageing*. 2005;34:561-566.
4. De Reuck J, Maurage CA, Deramecourt V, et al. Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: a neuropathological study. *Folia Neuropathologica*. 2018;56(2):81-87.
5. Yassi N, Hilal S, Xia Y, et al. Influence of Comorbidity of Cerebrovascular Disease and Amyloid- $\beta$  on Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2020;73(3):897-907.

6. Launer LJ. Epidemiology of white matter lesions. *Topics in magnetic resonance imaging*. 2004;15:365-367.
7. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *British Medical Journal*. 2010;341.
8. O'Brien JT, Thomas A. Vascular dementia. *Lancet*. 2015;386:1698-1706.
9. Moulin S, Labreuche J, Bombois S, et al. Dementia risk after spontaneous intracerebral haemorrhage: A prospective cohort study. *The Lancet Neurology*. 2016;15(8):820-829.
10. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2\*-weighted gradient-echo MRI. *Brain*. 2004;127:2265-2275.
11. Reuck JLD. The significance of small cerebral bleeds in neurodegenerative dementia syndromes. *Aging and disease*. 2012;3(4):307-312.
12. Greenberg SM, Rosand J. Outcome markers for clinical trials in cerebral amyloid angiopathy. *Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis*. 2001;8:56-60.
13. Moulin S, Cordonnier C. Role of cerebral microbleeds for intracerebral haemorrhage and dementia. *Current neurology and neuroscience reports*. 2019;19.
14. Petterson J, Sathiyamoorthy G, Gao F-Q, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the sunnybrook dementia study. *Archives of neurology*. 2008;65(6):790-795.
15. Natté R, Maat-Schieman M, Haan J, Bornebroek M, Roos RA, Duinen SGv. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. *Annals of neurology*. 2001;50(6):765-772.
16. Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain*. 2017;140:1829-1850.
17. Cao L, Tan L, Wang HF, Jiang T, Zhu XC, Yu JT. Cerebral microinfarcts and dementia: a systematic review and metaanalysis. *Current Alzheimer research*. 2017;14(7):802-808.

18. Kim KW, MacFal JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in the elderly. *Biological psychiatry*. 2008;64(4):273-280.
19. Gouw AA, Seewann A, Flier WMvd, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *Journal of neurology, neurosurgery, and psychiatry*. 2011;82:126-135.
20. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. *Stroke*. 1997;28(6):52-59.
21. Conklin J, Silver FL, Mikulis DJ, Mandell DM. Are Acute Infarcts the Cause of Leukoaraiosis? Brain Mapping for 16 Consecutive Weeks. *Annals of Neurology*. 2014;76(6):899-904.
22. Fazekas F, Chawluk JB, Alavi A, Hurtiq HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *American journal of roentgenology*. 1987;149(2):351-356.
23. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: Histopathological correlation of neuroimaging. *Cerebrovascular diseases*. 2011;32:528-534.
24. Goos JDC, Teunissen CE, Veerhuis R, et al. Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. *Neurobiology of aging*. 2012;33(5).
25. Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: A review of clinical, genetic, and neuroimaging associations. *Frontiers in Neurology*. 2014;4(Article 205).
26. Cordonnier C, Al-Shahi SR, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. *Brain*. 2007;130:1988-2003.
27. Greenberg SM, Vermooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. *Lancet neurology*. 2009;8:165-174.
28. Reuck JD, Deramecourt V, Cordonnier C, Leys D, Pasquier F, Maurage C. Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: A neuropathological study. *Journal of the neurological sciences*. 2011;300:63-66.

29. Buch S, Cheng YN, Hu J, et al. Determination of detection sensitivity for cerebral microbleeds using susceptibility weighted imaging. *NMR in biomedicine*. 2017;30(4).
30. Heuvel TLAvd, Eerden AWvd, Manniesing R, Ghafoorian M, Tan T, Andriessen TMJC. Automated detection of cerebral microbleeds in patients with traumatic brain injury. *Neuroimage: clinical*. 2016;12:241-251.
31. Ghafaryasl B, Lijn FVD, Poels M, Vrooman H, Ikram MA, Niessen WJ. A computer aided detection system for cerebral microbleeds in brain MRI. *9th IEEE International Symposium on Biomedical Imaging (ISBI)*. 2012:138-141.
32. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. *Journal of neural transmission*. 2002;109:813-836.
33. Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology*. 2010;74(17):1346-1350.
34. Veluw SJv, Shih AY, Smith EE, et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. *Lancet neurology*. 2017;16(9):730-740.
35. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS medicine*. 2009;6(7).
36. Sarro L, Tosakulwong N, Schwarz CG, et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimers dementia*. 2017;13(3):257-266.
37. Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. *Journal of neurology, neurosurgery and psychiatry*. 1999;67:66-72.
38. Park H-E, Park I-S, Oh Y-S, et al. Subcortical white matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism. *Journal of the neurological sciences*. 2015;353:44-48.
39. Koikkalainen J, Rhodius-Meester H, Tolonen A, et al. Differential diagnosis of neurodegenerative diseases using structural MRI data. *NeuroImage: Clinical*. 2016;11:435-449.

40. Joki H, Higashiyama Y, Nakae Y, et al. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease. *Journal of the neurological sciences*. 2018;385:99-104.
41. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. *International journal of geriatric psychiatry*. 2000;15:911-916.
42. Kim SW, Chung SJ, Oh Y-S, et al. Cerebral microbleeds in patients with dementia with Lewy bodies and Parkinson disease dementia. *American journal of neuroradiology*. 2015;36(9):1642-1647.
43. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. *Mov Disord*. 2006;21(2):223-229.
44. Daida K, Tanaka R, Yamashiro K, et al. The presence of cerebral microbleeds is associated with cognitive impairment in Parkinson's disease. *Journal of the Neurological Sciences*. 2018;393:39-44.
45. Slawek J, Roszmann A, Robowski P, et al. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. *Neurodegenerative Diseases*. 2013;12(1):1-12.
46. Ham JH, Yi H, Sunwoo MK, Hong JY, Sohn YH, Lee PH. Cerebral microbleeds in patients with Parkinson's disease. *J Neurol*. 2014;261(8):1628-1635.
47. Compta Y, Buongiorno M, Bargallo N, et al. White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson's disease. *Journal of the Neurological Sciences*. 2016;367:284-290.
48. Shin J, Choi S, Lee JE, Lee HS, Sohn YH, Lee PH. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. *Journal of Neurology, Neurosurgery and Psychiatry*. 2012;83(3):315-321.
49. Marshall GA, Shchelchkov E, Kaufer DI, Ivanko LS, Bohnen NI. White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. *Acta Neurol Scand*. 2006;113(2):87-91.

50. Kandiah N, Zainal NH, Narasimhalu K, et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. *Parkinsonism & Related Disorders*. 2014;20(11):1203-1208.
51. Sunwoo MK, Ham JH, Lee J, Sohn YH, Lee PH. The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease. *Movement Disorders*. 2014;29:S366-S367.
52. Lee SJ, Lee DG. The cross-sectional and longitudinal relationships between white matter hyperintensities and dementia in patients with Parkinson's disease: A retrospective analysis of 132 patients in a single center. *Arch Gerontol Geriatr*. 2016;62:133-137.
53. Gonzalez-Redondo R, Toledo J, Clavero P, et al. The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. *Eur J Neurol*. 2012;19(8):1100-1107.
54. Park YW, Shin NY, Chung SJ, et al. Magnetic Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease. *Movement Disorders*. 2019;19:19.
55. Dadar M, Gee M, Shuaib A, Duchesne S, Camicioli R. Cognitive and motor correlates of grey and white matter pathology in Parkinson's disease. *NeuroImage: Clinical*. 2020;27 (no pagination)(102353).
56. Nicoletti A, Luca A, Baschi R, et al. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study. *Journal of Neurology*. 2021;268(2):549-558.
57. Lee JE, Park B, Song SK, Sohn YH, Park H-J, Lee PH. A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. *Movement disorders*. 2010;25(1):28-34.
58. Fukui T, Oowan Y, Yamazaki T, Kinno R. Prevalence and clinical implication of microbleeds in dementia with Lewy bodies in comparison with microbleeds in Alzheimer's disease. *Dementia and geriatric cognitive disorders extra*. 2013;3:148-160.
59. Oppedal K, Aarsland D, Firbank MJ, et al. White matter hyperintensities in mild Lewy body dementia. *Dementia and geriatric cognitive disorders extra*. 2012;2:481-495.

60. Kenny RA, Shaw FE, O'Brien JT, Scheltens PH, Kalaria R, Ballard C. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. *Journal of neurology, neurosurgery and psychiatry*. 2004;75:966-971.
61. Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. *Annals of Neurology*. 2016;79(6):929-939.
62. Ghebremedhin E, Rosenberger A, Rub U, et al. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. *Journal of neuropathology & experimental neurology*. 2010;69(5):442-448.
63. Reuck JD, Deramecourt V, Cordonnier C, Leys D, Pasquier F, Maurage C-A. Prevalence of cerebrovascular lesions in patients with Lewy body dementia: A neuropathological study. *Clinical neurology and neurosurgery*. 2013;115:1094-1097.
64. Reuck JLD, Deramecourt V, Auger F, et al. Cerebrovascular lesions in mixed neurodegenerative dementia: A neuropathological and magnetic resonance study. *European Neurology*. 2017;78:1-5.
65. Choi S-A, Evidente VGH, Caviness JN, et al. Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia? *Acta Neuropathologica*. 2010;119(1):147-149.
66. De Reuck J, Auger F, Durieux N, et al. Topographic distribution of white matter changes and lacunar infarcts in neurodegenerative and vascular dementia syndromes: A post-mortem 7.0-tesla magnetic resonance imaging study. *European Stroke Journal*. 2016;1(2):122-129.
67. Reuck JLD, Auger F, Durieux N, et al. Detection of cortical microbleeds in portmortem brains of patients with Lewy body dementia: A 7.0-tesla magnetic resonance imaging study with neuropathological correlates. *European Neurology*. 2015;74:158-161.
68. Hase Y, Polvikoski TM, Firbank MJ, et al. Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. *Brain Pathology*. 2019;29:29.

69. Ihara M, Polvikoski TM, Hall R, et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. *Acta neuropathologica*. 2010;119:579-589.
70. Burton E, McKeith IG, Burn DJ, Firbank MJ, O'Brien JT. Progression of white matter hyperintensities in Alzheimer disease, dementia With Lewy bodies, and Parkinson disease dementia: A comparison with normal aging. *American journal of geriatric psychiatry*. 2006;14:842-849.
71. Ferreira D, Nedelska Z, Graff-Radford J, et al. Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. *Neurobiology of Aging*. 2021;105:252-261.
72. Ballard C, O'Brien J, Barber B, et al. Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. *Annals of the New York academy of sciences*. 2000;903:442-445.
73. Isojima D, Togo T, Kosaka K, et al. Vascular complications in dementia with Lewy bodies: A postmortem study. *Neuropathology*. 2006;26:293-297.
74. Gungor I, Sarro L, Graff-Radford J, et al. Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. *Parkinsonism and related disorders*. 2015;21:1101-1104.
75. Donaghy PC, Firbank M, Mitra D, et al. Microbleeds in dementia with Lewy bodies. *Journal of Neurology*. 2020;267(5):1491-1498.
76. Mendes A, Noblet V, Mondino M, et al. Association of cerebral microbleeds with cerebrospinal fluid Alzheimer-biomarkers and clinical symptoms in early dementia with Lewy bodies. *International Journal of Geriatric Psychiatry*. 2021;36(6):851-857.
77. Takemoto M, Yamashita T, Ohta Y, et al. Cerebral Microbleeds in Patients with Parkinson's Disease and Dementia with Lewy Bodies: Comparison Using Magnetic Resonance Imaging and 99 mTc-ECD SPECT Subtraction Imaging. *Journal of Alzheimer's disease : JAD*. 2021;80(1):331-335.
78. Janelidze S, Lindqvist D, Francardo V, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology*. 2015;85(21):1834-1842.
79. Polyakova TA, Levin OS. Cerebral Microbleeds in Cerebrovascular and Neurodegenerative Diseases with Cognitive Impairments. *Neuroscience and Behavioral Physiology*. 2017;47(9):1078-1085.

80. Olichney JM, Ellis RJ, Katzman R, Sabbagh MN, Hansen L. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer's disease. *Annals of the new york academy of sciences*. 1997;826(1):493-497.
81. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. *Acta neuropathologica*. 2008;115:427-436.
82. Jellinger KA, Attems J. Cerebral amyloid angiopathy in Lewy body disease. *Journal of neural transmission*. 2008;115:473-482.
83. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol*. 2012;72(4):587-598.
84. Jellinger KA. Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. *Journal of Neural Transmission*. 2021;128(5):687-699.
85. Hansen D, Ling H, Lashley T, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. *Neuropathology and Applied Neurobiology*. 2021;47(1):143-156.
86. Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. *Journal of neural transmission*. 2003;110:771-778.
87. Reuck JD. The impact of cerebral amyloid angiopathy in various neurodegenerative dementia syndromes: a neuropathological study. *Neurology research international*. 2019;2019.
88. Wu E, Lipton RB, Dickson DW. Amyloid angiopathy in diffuse Lewy body disease. *Neurology*. 1992;42:2131-2135.
89. Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. *Parkinsonism Relat Disord*. 2014;20(5):525-529.
90. De Reuck J, Deramecourt V, Cordonnier C, et al. The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. *J Neurol Sci*. 2016;366:164-166.
91. Londos E, Passant U, Brun A, Gustafson L. Clinical Lewy body dementia and the impact of vascular components. *International journal of geriatric psychiatry*. 2000;15:40-49.

92. Hilal S, Sikking E, Shaik MA, et al. Cortical cerebral microinfarcts on 3T MRI: A novel marker of cerebrovascular disease. *Neurology*. 2016;87(15):1583-1590.
93. Scheltens P, Barkhof F, Leys D, et al. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. *Journal of the neurological sciences*. 1993;114(1):7-12.
94. Gouw AA, Flier WMVd, Straaten ECWv, et al. Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. *Journal of neurology*. 2006;253:1189-1196.
95. Caligiuri ME, Perrotta P, Augimeri A, Rocca F, Quattrone A, Cherubini A. Automatic detection of white matter hyperintensities in healthy aging and pathology using magnetic resonance imaging: a review. *Neuroinformatics*. 2015;13:261-276.
96. Frey BM, Petersen M, Mayer C, Schulz M, Cheng B, Thomalla G. Characterization of white matter hyperintensities in large-scale MRI-studies. *Frontiers in neurology*. 2019;10.
97. Yassi N, Desmond DM, Masters CL. Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia. *Journal of Molecular Neuroscience*. 2016;60:349-353.
98. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *The Lancet Neurology*. 2013;12(8):822-838.

**Funding:** This work was supported by the Dementia Australia Research Fellowship award

**Table 1. Studies of MRI white matter hyperintensities in LBD**

	Number of DLB/PDD participants : n	MRI field strength/white matter hyper-intensity analysis method*	DLB v controls	DLB v AD	DLB v PDD	PDD v PD	PDD v controls
Barber 1999	DLB: 27	1T	↑	=			
Ballard 2000	DLB: 17	1T					
Kenny 2004	DLB: 38	1T		↑			
Beyer 2006	PDD: 16	1.5T				↑	=
Burton 2006	DLB: 26, PDD: 31	1.5T/automated	=				
Marshall 2006	PDD: 11	1.5T					↑
Rodriguez-Oroz 2009	PDD: 30	3T				=	=
Lee 2010	DLB: 18, PDD: 20	3T/automated			↑ <sup>†</sup>		
Gonzalez-Redondo 2012	PDD: 26	1.5				=	
Oppedal 2012	LBD: 16	1.5T/automated		=			
Shin 2012	PDD: 40	3T					
Fukui 2013	DLB: 59	1.5T		=			
Slawek 2013	PDD: 57	1.5T				↑	
Ham 2014	PDD: 36	3T				↑	↑
Kandiah 2014	PDD: 8	3T/automated					
Sunwoo 2014	PDD: 22	3T/automated					
Kim 2015	DLB: 42, PDD: 88	3T	↑		=		
Park 2015	DLB: 17, PDD: 21	3T	↑	=	=		
Compta 2016	PDD: 19	3T					
Koikkalainen 2016	DLB: 47	1,1.5,3T	↑				
Lee 2016	PDD: 36	1.5T					

Sarro 2017	DLB: 81	3T/automated	↑	↑ <sup>‡</sup>	
Daida 2018	PDD: 21	1.5T			↑
Joki 2018	DLB: 50, PDD: 50	1.5T	↑	=	↑
Park 2019	PDD: 34	3T			
Wang 2020	PDD: 31	3T			↑
Dadar 2020	PDD: 39	1.5T/automated			
Linortner 2020	PDD: 12	3T			
Ferreira 2021	DLB: 165	3T			
Nicoletti 2021	PDD: 18	1.5T			
Mendes 2021	DLB: 91	-		=	

SD: Standard Deviation; PM: Post-mortem; MRI: Magnetic Resonance Imaging; DLB: Dementia with Lewy Bodies; AD: Alzheimer's Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD)

\*For the remaining studies, a visual rating scale was used

†Increased in parietal and occipital regions only

‡Increased in occipital and posterior periventricular regions only

*Not all of the listed studies provided direct comparison between groups*

Author Manuscript

# Author Manuscript

This article is protected by copyright. All rights reserved

**Table 2: Neuropathological studies on white matter changes of presumed vascular origin in LBD**

	DLB/PDD participants: n	DLB v controls	DLB v AD	PDD v PD
Londos 2000	DLB: 48		↑ <sup>†</sup>	
Ghebremedhin 2010	DLB: 13	=		
Ihara 2010	DLB: 31	↑ <sup>‡</sup>		
Sun-Ah Choi 2010	PDD: 26			=
De Reuck 2011	LBD: 8	=		
De Reuck 2012	LBD: 20	=		
De Reuck 2013	LBD: 24	=		
De Reuck 2015	LBD: 15	↑		
Hase 2019	DLB: 24, PDD: 18	↑		
De Reuck 2016	LBD: 7	=		
De Reuck 2017	LBD: 24		=	

SD: Standard Deviation; DLB: Dementia with Lewy Bodies; AD: Alzheimer's

Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD),

↑ Increased in frontal region only, grouped white matter lesions together including infarcts, traumatic WM damage, unspecified WM degeneration

‡ In the frontal region, not significant for temporal region

**Table 3. Studies on cerebral micro-bleeds and minibleeds in LBD**

	DLB/PDD participants: n	MRI Sequences	DLB v controls	DLB v AD	DLB v PDD	PDD v PD	PDD v controls	Reported CMB prevalence
Fukui 2013	DLB: 59	1.5T/T2 GRE		=				DLB: 16.9%, AD: 19.8%
Ham 2014	PDD: 36	3T/T2*GRE				↑	↑	PDD: 36%, PD with MCI: 15%, PD: 15%, controls: 12%
Kim 2015	DLB: 42, PDD: 88	3T/T2 GRE	↑		↑			DLB: 45.2%, PDD: 26.1%, controls: 17.1%
Gungor 2015	DLB: 23	3T/3D MPRAGE + T2 GRE		=				DLB: 30%, AD: 24%
Yamashiro 2015	PDD: 52	1.5/T2* GRE						-
Polyakova 2017	DLB: 25	1.5/T2* GRE				↑		-
Daida 2018	PDD: 21	1.5/T2* GRE						PDD: 48%, PD: 8%
Isojima 2006	DLB: 25	-		= minib				DLB: 12%, AD: 6% (minib)
De Reuck 2011	LBD: 8	-	CMB =, minib ↑					LBD CMB: 0, minib: 75%, AD CMB: 17.8%, minib: 88.8%, controls CMB: 0, minib: 60%
De Reuck 2012	LBD: 20	-	CMB =, minib ↑					LBD minib: 80%, controls: 50%
De Reuck 2013	LBD: 20	-	CMB =, minib ↑					LBD and control CMB: 0, LBD minib: 80%, controls: 43%
De Reuck 2016	LBD: 7	-	=					-
De Reuck 2015	LBD: 15	7T/T2 GRE	↑					
De Reuck 2015	LBD: 10	7T/positioning sequence, T2, T2*	= ‡					LBD: 40%, controls: 31%
De Reuck 2017	LBD: 24	7T/T2 and T2* GRE		=				-
Donaghy 2020	DLB: 30	3T/3D MPRAGE, T2*	=	=				DLB: 40%, AD: 50%, controls: 15%

Mendes 2021	DLB: 91	3D FLAIR, T2* GRE	=	DLB: 24%, AD: 37%
Takemoto 2021	DLB: 17	T2*		DLB: 41%, PD: 11%

PM: Post-mortem; MRI: Magnetic Resonance Imaging; DLB: Dementia with Lewy Bodies; AD: Alzheimer's Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD); minib = mini-bleeds; MPRAGE: Magnetization prepared rapid acquisition gradient echo; DIR: Double inversion recovery

<sup>†</sup>Only increased in frontal regions on MRI, but overall increased in neuropathology examination using 1 standard coronal section

<sup>‡</sup>Cerebellar microbleeds only studied, no significant difference in either MRI or neuropathological examination

**Table 4. Studies on cerebral amyloid angiopathy (CAA) in LBD**

	<b>DLB/PDD participants : n</b>	<b>Reported CAA prevalence</b>
Wu 1992	DLB: 67	DLB with AD: 85%, DLB without AD: 58%, AD: 100%, controls 50%
Jellinger 2003	DLB: 96	Moderate-severe CAA in DLB with AD: 78%, DLB without AD: 28%, AD: 98%
Jellinger 2008 a	DLB: 20	-
Jellinger 2008 b	DLB: 20	-
Ghebremedhin 2010	DLB: 13	-
Jellinger 2010	DLB: 106	DLB: 41%, PD: 35%, AD: 98%, controls: 30%
Compta 2011	PDD: 29	-
De Reuck 2011	DLB: 8	DLB: 13%, AD: 58%, controls: 0
Irwin 2012	PDD: 92	PDD: 24%, PDD with AD pathology: 41%, PDD without AD (12%), PD: 3%
De Reuck 2013	DLB: 20	-
Dugger 2014	DLB: 90	-
De Reuck 2018		-
De Reuck 2019	DLB: 21	DLB: 45%, AD: 67%, controls: 0
Hase 2019	DLB: 24, PDD: 18	DLB: 8%, PDD: 6%, AD: 67%
Hansen 2020	DLB: 16, PDD: 52	DLB: 100%, PDD: 64%
Jellinger 2021	PDD: 110, DLB: 60	DLB: 93%, PDD: 50%, PD: 22%

DLB: Dementia with Lewy Bodies; AD: Alzheimer's Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD); DLB+AD: DLB with AD co-pathology

**Table 5. Large cortical infarcts and small subcortical infarcts and intracerebral haemorrhage in LBD**

	DLB participants:		DLB v	DLB v	DLB v	DLB v
	n	controls	AD	PDD	PD	PD
Kim 2015	42	= (inf)		= (inf)		
Koikkalainen 2016	47	= (inf)	= (inf)			
Sarro 2017	81	= (inf)				
Londos 2000	48		↑ <sup>†</sup> (inf)			
Jellinger 2003	96	= <sup>‡</sup> (inf, H)				= <sup>‡</sup> (inf, H)
Isojima 2006	25		= (inf) ↑ (H)			
Ghebremedhin 2010	13	= (inf)				
De Reuck 2011	8	= (inf, H)				
De Reuck 2012	20	= (inf, H)				
De Reuck 2013	24	= (inf, H)				
Dugger 2014	81					
De Reuck 2016	73	= (inf, H)				
Park 2019	34					
De Reuck 2015	15	= (inf, H)				
De Reuck 2017	24		= (inf, H)			
Wang 2020	62					
Ferreira 2021	165					

DLB: Dementia with Lewy Bodies; AD: Alzheimer's Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD); inf: Infarcts, including "lacunar infarcts", H: Haemorrhages

<sup>†</sup>Studied frontal white matter changes, including both non-specific white matter changes and infarcts

<sup>‡</sup>Included both haemorrhages and infarcts together


*Not all of the listed studies provided direct comparison between groups*

**Table 6. Studies on micro-infarcts in LBD**

	DLB participants: n	DLB v controls	DLB v AD	Reported micro-infarct prevalence
Isojima 2006	25		↓	DLB: 40%, AD: 68%.
Ghebremedhin 2010	13	↑		-
De Reuck 2011	8	=		DLB: 18%, controls: 10%.
De Reuck 2012	20	=		-
De Reuck 2013	24	=		DLB: 15%, controls: 21%
De Reuck 2016	7	=		-
De Reuck 2018	-			-
Hase 2019	DLB: 24, PDD: 18	↑		DLB: 80%, PDD: 89%, controls: 35%
De Reuck 2014	16			-
De Reuck 2015	15	↑		-
De Reuck 2015*	10	= <sup>†</sup>		DLB: 50%, controls: 19%
De Reuck 2017	24		↑	-

DLB: Dementia with Lewy Bodies; AD: Alzheimer's Dementia; PDD: Parkinson's Disease Dementia, LBD: Lewy body dementia (DLB + PDD)

<sup>†</sup>Examined cerebellum only

**Fig 1. PRISMA flow chart for included and excluded studies.**

\*Some studies included multiple lesion types




Fig 2. A) Peri-ventricular and B) deep white matter hyper-intensities

ene\_15211\_f2.png